Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor John Gilmer

Professor in Pharmaceutical Chemistry (Pharmacy)
Head of School (School Office - Pharmacy & Pharmceut Sci)
25/6/7 WESTLAND ROW
      
Profile Photo

Professor John Gilmer

Professor in Pharmaceutical Chemistry (Pharmacy)
25/6/7 WESTLAND ROW

Head of School (School Office - Pharmacy & Pharmceut Sci)


  ASPIRIN   BINDING   BIOLOGICAL-MEMBRANES   BUTYRYLCHOLINESTERASE   Design, synthesis and testing of specific enzyme inhibitors   ENZYME SUBSTRATE SPECIFICITIES   HOST-GUEST CHEMISTRY   HYDROLYSIS   IMPROVED DELIVERY   Isosorbide-based therapies for Alzheimer's disease   MOLECULAR RECOGNITION   PRODRUG   Pro-drug design for tissue targeting   RECEPTORS   STEROIDS   Thyrotropin-releasing hormone-degrading ectoenzyme inhibitors in the treatment of CNS disorders
Project Title
 Development of novel aspirin prodrugs
From
To
Summary
Regular aspirin use is associated with reduced risk of mortality in all cardiovascular risk groups. This effect is attributed to aspirin's inhibition of platelet COX-1. In addition, numerous observational studies indicate that aspirin use reduces the risk of colorectal, oesophageal, gastric and lung cancers. Aspirin's cytoprotective effects have been attributed to its unique ability to acetylate COX-2, which causes arachidonic acid to be shunted away from PGE2, a cancer promoter, towards HETE, a cancer suppressor. There are not yet reliable dose-related data for the prophylactic use of aspirin in cancer; however, it seems likely to be higher than the optimal dose required for its established role in the prevention of heart attack. Other findings suggest a protective role for aspirin in Alzheimer's disease and other forms of dementia. The main side effect associated with aspirin use is gastric bleeding. Endoscopically controlled studies demonstrate an increased risk of bleeding at all doses (75mg = 2.3, 150 mg =3.2, 300 mg = 3.9): in one recent study 10% of patients on low dose aspirin (10-300 mg/day) had endoscopic ulcers after 12 weeks, with one case occurring at 10 mg/day. Elevated bleeding was observed in several studies 5 to 30 days after the start of therapy indicating that adaptation does not occur. Significantly, the risk of GI side-effects has limited aspirin use to patient groups with a high probability of a thrombotic event. A potentially valuable approach to this problem is the design of aspirin derivatives capable of delaying aspirin-release until after absorption. This would effectively abolish the local component of gastric toxicity, associated with direct contact between the aspirin carboxylic acid and the gastric mucosa. Secondly, prostaglandin levels in the gastric microcirculation should be unaffected during the first pass since aspirin esters do not have intrinsic cyclo-oxygenase inhibitory activity. This project is concerned with a novel design that will permit for the first time the dual release of aspirin and nitric oxide from the same drug molecule.
Funding Agency
Enterprise Ireland
Programme
POC, Tech Dev, Innovations
Project Type
applied
Project Title
 Probing the interaction of ursodeoxycholic acid with the steroid receptor
From
2006
To
2016
Summary
Ursodeoxycholic acid (UDCA) has been found to act as a bile secretatogue, immunomodulator and inhibitor of cellular apoptosis. There is some evidence that UDCA activates the glucocorticoid receptor binding to a different region of the ligand binding domain to GR agonists such as dexamethasone. Activation of the GR might then result in a differential regulation of gene expression. In addition it is known that some of UDCAs actions are due to suppression of Activator Protein-1 (AP-1) and Nuclear Factor kappa B (NF-κB). Hence UDCA could act as a prototype for the development of a novel and more selective modifier of the GR creating a class of drugs with inflammatory activity but reduced side effects. This project is a collaboration with Aideen Long at the IMI (St James's) and it uses conventional medicinal chemistry structure-function surveys in combination with high throughput screening (Cellomics) and in silico models of the glucocorticoid receptor. Collaborators: Aideen Long, Dermot Kelleher. Recipient: Ruchika Sharma
Funding Agency
HRB , IRCSET
Project Type
Basic
Project Title
 Investigation into highly potent inhibitors of butyrylcholinesterase
From
To
Summary
The central nervous system contains two cholinesterases; acetylcholinesterase [EC 3.1.1.7; AChE] and butyrylcholinesterase [EC 3.1.1.8; BuChE]. These are probably the most widely studied enzymes due to their extraordinary speed and the important relationship between AChE and the neurotransmitter acetylcholine (ACh). Surprisingly, no physiological role has been assigned to BuChE, nor has it a known endogenous substrate (Darvesh et al., 2003). It is difficult to accept that this enzyme has been retained without function in the evolving organism: for the present it takes its name from butyrylcholine, a synthetic substance it hydrolyses exceedingly rapidly. Interest in BuChE has risen sharply due to emerging evidence of its involvement in Alzheimer's disease (Giacobini, 2003, 2004). We have recently discovered that human BuChE hydrolyses some isosorbide-2-esters at higher rates than butyrylcholine itself (Gilmer et al., 2002, 2005). We hypothesised that this could be used in the design of novel inhibitors of BuChE. Our design involved replacement of the vulnerable ester with carbamate functionality, which is esterase inhibitory. The approach proved highly successful. Many of the compounds in the new class exhibit nanomolar potency. The current lead compound has an IC50 of 150 picoM and more than 65,000-fold selectivity for BuChE over AChE. It is the most potent and BuChE-selective compound ever reported. It is also completely unlike any other BuChE inhibitor or substrate type. Furthermore, it is uncharged at physiological pH and highly lipophilic, attributes generally required for good blood brain barrier penetrability. These compounds hold significant promise in probing the biological role of BuChE and potentially in Alzheimer's therapy. The aim of this project is to find out how the esters and carbamates interact with both cholinesterases and to begin exploring their therapeutic potential using medicinal chemistry in combination with clinically relevant models of AD. The overall purpose of the program is to examine the hypothesis that BuChE is a rogue protein in AD. Collaborators: Sean Reidy, Sheila Ryder
Funding Agency
SFI
Project Type
Basic Research

Details Date
Member, DMMC Cancer Principal Investigators, Trans-institutional grouping of Principal Investigators leading research on Cancer themes
Member, Core Technology PI's, DMMC Principal Investigators leading the development of core technology platforms.
Member, Centre for Research into Global Disease (Proposed), This consortium combines researchers with complementary interests in globally significant infectious disease. Interests include innate immunity, immune regulation, regional immunity, immune evasiob, vaccine & adjuvant development as well as drug & target development.
Invitee, Colorectal & GI Cancer Research Group (Proposed), Speculative idea to cluster PI's around collaborative study on Upper GI and Colon Cancers.Deliberately wide selection of surgeons, pathologists and academic researchers based on stated interest or publication in fields of oesophageal or colorectal cancer.To be reviewed/focused by DK/JR/PMacM.Extracted from DMMC Research Database - 8 Nov 2004.
Member, PHG Funded PI's and Researchers, All Researchers funded under Cycle 3 PRTLI - Programme for Human Genomics
Details Date From Date To
Member of European Federation of Pharmaceutical Scientists
Murnane C., Gardiner N., Crehan O., Bacon C.L., McHugh R., Gilmer J.F., Mantalaris A., Panoskaltsis N., Chimeric Antigen Receptor-T (CAR-T) Cells as " Living Drugs ": A Clinical Pharmacist Perspective, Journal of Clinical Pharmacy and Therapeutics, 2024, 2024, Journal Article, PUBLISHED  DOI
John Gilmer, Jason Gavin, 'CoCompounds for use in the treatment of liver disease ', Trinity College Dublin, 2022, 28 April 2023, College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin , Patent, SUBMITTED  URL
Zaufel A, van de Wiel SMW, Yin L, Fauler G, Chien D, Dong X, Gilmer JF, Truong JK, Dawson PA, van de Graaf SFJ, Fickert P, Moustafa T., Secondary (iso)BAs cooperate with endogenous ligands to activate FXR under physiological and pathological conditions., Biochim Biophys Acta Mol Basis Dis, 1867, (8), 2021, p166153 , Journal Article, PUBLISHED  DOI
Quilty F, Freeley M, Gargan S, Gilmer J, Long A., Deoxycholic acid induces proinflammatory cytokine production by model oesophageal cells via lipid rafts., The Journal of steroid biochemistry and molecular biology, 214, 2021, p105987 , Journal Article, PUBLISHED  DOI
Watson C., Spiers J.P., Waterstone M., Russell-Hallinan A., Gallagher J., McDonald K., Ryan C., Gilmer J., Ledwidge M., Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: a report from the STOP-HF follow-up programme, BMC Cardiovascular Disorders, 21, (1), 2021, Journal Article, PUBLISHED  DOI
Quilty F, Byrne AM, Aird J, El Mashad S, Parra-Blanco A, Long A, Gilmer JF, Medina C., Impact of Deoxycholic Acid on Oesophageal Adenocarcinoma Invasion: Effect on Matrix Metalloproteinases., International journal of molecular sciences, 21, (21), 2020, Journal Article, PUBLISHED  DOI
O†sullivan, S. and Wang, J. and Radomski, M.W. and Gilmer, J.F. and Medina, C., Novel barbiturate-nitrate compounds inhibit the upregulation of matrix metalloproteinase-9 gene expression in intestinal inflammation through a CGMP-mediated pathway, Biomolecules, 10, (5), 2020, Notes: [cited By 3], Journal Article, PUBLISHED  DOI
Phipps SM, Garry CE, Kamal S, Johnson JD, Gilmer J, Long A, Kelleher D, Duggan SP., High Content Imaging of Barrett's-Associated High-Grade Dysplasia Cells After siRNA Library Screening Reveals Acid-Responsive Regulators of Cellular Transitions., Cellular and molecular gastroenterology and hepatology, 10, (3), 2020, p601-622 , Journal Article, PUBLISHED  DOI
Krzywonos-Zawadzka A, Franczak A, Olejnik A, Radomski M, Gilmer JF, Sawicki G, Woźniak M, Bil-Lula I., Cardioprotective effect of MMP-2-inhibitor-NO-donor hybrid against ischaemia/reperfusion injury., J Cell Mol Med. , 23, (4), 2019, p2836 - 2848, Journal Article, PUBLISHED  TARA - Full Text
Maria Pigott, Jun Wang, Shane O"Sullivan, Carlos Medina and John F Gilmer , Design of Matrix Metalloproteinase Inhibitors for Inflammatory Bowel Disease , Pharmaceuticals, 27th Annual GP2A Medicinal Chemistry Conference, Nottingham University, 2019/12/6, edited by Shailesh N Mistry, Pascal Marchand, Barrie Kellam , 12, (4), MDPI, 2019, pp179-, Poster, PUBLISHED
  

Page 1 of 10
Toware Gaseous Mediator Hybrid Drugs in, editor(s)Michael Decker , Design of Hybrid Molecules for Drug Development, Oxford : Elsevier, 2017, pp47-81 , [John F. Gilmer], Book Chapter, PUBLISHED
N Glezeva, C Watson, J Baugh, K McDonald, J Gilmer, C Martin, M Santos Martinez, M Ledwidge, Association between low-dose aspirin use, monocyte biomarkers, matrix metalloproteinases and outcome in HFpEF, BMJ Publishing Group Ltd and British Cardiovascular Society, 102, (supplement 9), 2017, ppA5 , Conference Paper, PUBLISHED
Fran Quilty, "Mechanistic Studies into the Effect of Deoxycholic Acid on Oesophageal Cancer Initiation and Progression", 2016, Notes: [PhD Thesis], Thesis, PUBLISHED
Shivashini Kirthi Jeyarajah, Barry Hall, Mary Hussey, John Gilmer, Jun Wang, Carlos Medina, Deirdre McNamara, Low Infliximab Trough Levels Are Not Predictive of Disease Activity in Clinical Practice, Gastroenterology, 148, (4), 2015, ppS-8Am 65 , Conference Paper, PUBLISHED
S Etzbach, JJ Salomon, F Májer, MN Mohd Najib, CM Lehr, JF Gilmer, C Ehrhardt, Fluorescence-labelled bile acids as novel tools to measure organic anionic transporting polypeptide (OATP) function, AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside, Bethesda, MD, 14-16/03/2011, 2011, ppW3020 , Meeting Abstract, PUBLISHED
JJ Salomon, S Etzbach, F Májer, JF Gilmer, CM Lehr, C Ehrhardt, Fluorescent bile acids for the assessment of organic anionic transporting polypeptide (OATP) function, AAPS J, 25th Annual Meeting of the AAPS, Washington, DC, 23-27/10/2011, 13, (S2), 2011, ppT2119 , Meeting Abstract, PUBLISHED

  


Award Date
Visitng Professor in Medicine Chemistry, University of Wurzburg 2014-
Winner, Big Ideas, Enterprise Ireland for Commercialization in The Life Sciences 2010
i) Enzyme inhibitors . Isosorbide-based inhibitors of butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE): synthesis and biochemistry; the role of BuChE in Alzheimer's disease . Rational design of selective covalent inhibitors of COX-2 . Rational design, synthesis and testing of inhibitors for thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) ii) Prodrugs and metabolic hydrolysis . Design and evaluation of aspirin-based antiplatelet agents with reduced gastric toxicity relative to aspirin . Intelligent prodrug carrier systems for targeting corticosteroids to the colon . Exploring metabolic vectors for site specific drug delivery